Webb, Edward J. D. http://orcid.org/0000-0001-7918-839X
Meads, David
Eskytė, Ieva
Ford, Helen L. http://orcid.org/0000-0002-4156-5046
Bekker, Hilary L. http://orcid.org/0000-0003-1978-5795
Chataway, Jeremy http://orcid.org/0000-0001-7286-6901
Pepper, George
Marti, Joachim http://orcid.org/0000-0001-5763-3704
Okan, Yasmina
Pavitt, Sue H.
Schmierer, Klaus http://orcid.org/0000-0002-9293-8893
Manzano, Ana
Funding for this research was provided by:
Multiple Sclerosis Society (30)
National Institute for Health Research
Cancer Research UK (57775/A22183)
Article History
First Online: 25 June 2020
Compliance with Ethical Standards
:
: This study was funded by the UK Multiple Sclerosis Society (grant no. 30). The research is supported by the National Institute for Health Research (NIHR) infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. YO acknowledges support from a Population Research Fellowship awarded by Cancer Research UK (reference C57775/A22182). JC is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.
: Jeremy Chataway has received support from the Efficacy and Mechanism Evaluation Programme and Health Technology Assessment Programme (NIHR); UK Multiple Sclerosis Society and National Multiple Sclerosis Society; and the Rosetrees Trust. In the last 3 years, he has been a local principal investigator for trials in MS funded by Receptos, Novartis and Biogen Idec, and has received an investigator grant from Novartis outside this work. He has taken part in Advisory Boards/consultancy for Roche, Merck, MedDay, Biogen and Celgene. Klaus Schmierer has received consulting fees from Biogen, Merck, Novartis and Roche, and has received payments for lecturing activities from Biogen, Merck, Novartis, Roche and Teva. Hilary L. Bekker provides guidance, based on her academic expertise in medical decision making, to health policy organisations, patient advocacy groups, health professionals and health scientists on research methods and techniques to develop and evaluate patient decision aids and shared decision making interventions. Her time and expenses in attending meetings, carrying out evaluations and collaborating with other projects are remunerated. She does not gain financially from the outcomes or outputs of these collaborations. Helen Ford has received support from the Health Technology Assessment Programme (NIHR) and the UK MS Society. In the past 3 years, Helen Ford has been a local principal investigator for trials in MS funded by Novartis, Roche, and Biogen Idec and has taken part in advisory boards and consultancy for Merck, Teva, Biogen, and Novartis. Edward Webb, David Meads, Ieva Eskytė, George Pepper, Joachim Marti, Yasmina Okan, Sue Pavitt, and Ana Manzano have no conflicts of interest to declare.
: All participants gave informed consent before completing the survey, as well as consent to merge their responses with data from the UK MS Register.
: Approval for this study was given by a National Health Service (NHS) Research Ethics Committee.